Insights: News
As a diagnostics platform company that provides serious or complex laboratory testing, Mayo Clinic Laboratories is constantly working to advance patient care and broaden access to specialized testing. Learn about the latest news from Mayo Clinic Laboratories here, including new test launches, collaborations, operational updates, and more.
Most recent posts
Christopher Garcia, M.D., shares how secure digital tools, wearable data, and AI can enable more personalized diagnostic pathways, while still keeping clinicians in the driver’s seat.
Mayo Clinic Laboratories (MCL) is pleased to announce an essential update to our CPT code communication process and website layout. This change is designed to bring timely notifications for accurate billing information.
New diagnostic tests specifically for conditions that predominantly or only affect women, such as autoimmune diseases and gynecological cancers, are empowering female patients and their physicians to make informed decisions.
The Lupus Foundation of America estimates that at least five million people worldwide have a form of lupus. Yet, the most widely used laboratory tests for patients with this complex condition were developed more than 60 years ago, and physicians need modern, evidence-based tools to provide high-quality care for their patients. That is why Mayo Clinic Laboratories and Progentec Diagnostics joined forces to provide solutions that transform that experience.
Mayo Clinic researchers identify a new subtype of MGTS, linked to recurrent blood clots, with significant diagnostic challenges and treatment implications.
Clinical labs are key to advancing health equity, reducing barriers, and improving access through innovation, collaboration, and community engagement. Dr. Morice shares his thoughts in the Lab Manager article, “Health Equity Starts in the Lab: Here’s How.”
Fergus Couch, Ph.D., chair of Mayo Clinic’s Division of Experimental Pathology and Laboratory Medicine, led a team that recently published new National Institutes of Health and U.S. Food and Drug Administration-approved guidelines for the interpretation of variants in the ataxia telangiectasia mutated (ATM) cancer gene. Inherited mutations in ATM have been shown to increase the risk of breast, pancreatic, and prostate cancers. Now published by the American Journal of Human Genetics and available for widespread use, Dr. Couch says the guidelines can help clinicians around the world apply the same consistent method of classification to ATM variants.
William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, recently shared with the Advisory Board his insight into the potential that digital pathology and out-of-lab testing can bring into the laboratory space.
Due to the Thanksgiving holiday (recognized on Thursday, Nov. 28), Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered. To ensure specimen stability and prevent delays, follow the guidelines outlined below for domestic clients and international clients.
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.
Dr. Leslie Donato recently joined “Laborastories: The Podcast,” hosted by the Association for Diagnostics & Laboratory Medicine (ADLM) president Dr. Anthony Killeen, to discuss the publication of the new ADLM lipid and lipoprotein testing document. The document highlights best practices and new guidance regarding lipid and lipoprotein testing to ensure the best care for patients with heart disease, while educating clinical laboratorians on the most recent evidence-based improvements in the testing space.
Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Alicia Algeciras-Schimnich,[...]